comparemela.com

Latest Breaking News On - National cancer center hospital east - Page 12 : comparemela.com

Chula Makes Progress in CAR T-Cell Therapy Innovation: New Hope for Thai Lymphoma Cancer Patients

Chulalongkorn University, Thailand, and Nagoya University, Japan, in their collaboration to develop an immunotherapy method for curing cancer, reported on the progress of CAR T-cell immunotherapy innovation for treating cancer in leukemia and B-cell lymphoma patients, which can increase survival rates and reduce cancer recurrence. BANGKOK, April 6, 2023 /PRNewswire/ Chulalongkorn University and the Faculty of Medicine, Chulalongkorn University, organized the17thChula the Impact on "CAR T-Cell Cancer Therapy Innovation: New Hope for Thai Cancer Patients"on Tuesday, March 28, 2023, at Saranitet Conference Room, Chulalongkorn Auditorium. The talk presented the progress of CAR T-cell immunotherapy innovation for treating cancer in leukemia and B-cell lymphoma patients. This research project is a collaboration between the Cancer Immunotherapy Excellence Center, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, Thailand, and Tokai National Hi

Colorectal cancer: New blood test may help determine if chemotherapy is needed after surgery

Frontline Zolbetuximab Plus Chemo May Be New Standard Care for Gastric/GEJ Cancer

Adding zolbetuximab to standard frontline chemotherapy can improve outcomes in certain patients with gastric/GEJ cancer, a phase 3 study suggests.

Natera Announces Publication of Prospective, Multi-Site CIRCULATE Study in Nature Medicine Demonstrating Signatera s Ability to Predict Chemotherapy Benefit in Colorectal Cancer Seite 1

17.01.2023 - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new study in Nature Medicine, which demonstrates the ability of the SignateraTM molecular residual disease (MRD) test to identify patients . Seite 1

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.